Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of NVD003 versus iliac crest bone graft in pediatric congenital pseudarthrosis of the tibia
2025-520998-39-00Phase 3Authorised
- Sponsor
- Novadip Biosciences
- Start
- Sep 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of NVD-003 in congenital pseudarthrosis of the tibia (CPT) (2 arms), sponsored by Novadip Biosciences. Primary endpoint: Overall healing at 12 months. Planned start Sep 2025; status: authorised.
02
Drugs
NVD-003
03
Conditions
congenital pseudarthrosis of the tibia (CPT)
Beyond the preview
Go deeper on 2025-520998-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520998-39-00.